GlassScriptPhysician profile
Stephen J Matse
NPI 1427054642
$8,315.74
in general payments reported to CMS, 2019-2025
40 companies · $944 in 2025
The $944 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,169 · 2020: $1,135 · 2021: $1,238 · 2022: $1,522 · 2023: $1,196 · 2024: $1,111 · 2025: $944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,251.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,154.97 | 2021-2025 | |
| Pfizer INC. | $991.24 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $730.13 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $706.46 | 2019-2025 | Rybelsus, Ozempic |
| Allergan, INC. | $664.62 | 2019-2020 | |
| Lilly USA, LLC | $626.49 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $420.30 | 2021-2025 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $347.86 | 2019-2021 | |
| Glaxosmithkline, LLC. | $295.04 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $226.45 | 2019-2025 | Eliquis |
| Astellas Pharma US INC | $207.70 | 2019-2024 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $179.53 | 2019-2022 | |
| Amgen INC. | $171.60 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $169.84 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $163.02 | 2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Matse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.